India
# |
Name |
Operating Income Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
85.27%
|
March 31, 2024 | USD 6.89 | -1.28% |
|
India |
|
2 |
79.28%
|
March 31, 2024 | USD 11.85 | 8.40% |
|
India |
|
3 |
64.87%
|
March 31, 2024 | USD 14.52 | 3.84% |
|
India |
|
4 |
62.74%
|
March 31, 2024 | USD 26.89 | 2.81% |
|
India |
|
5 |
57.67%
|
March 31, 2024 | USD 2.20 | 4.28% |
|
India |
|
6 |
57.36%
|
March 31, 2024 | USD 7.15 | 0.36% |
|
India |
|
7 |
54.87%
|
March 31, 2024 | USD 0.81 | 0.29% |
|
India |
|
8 |
52.72%
|
June 30, 2024 | USD 61.83 | 3.06% |
|
India |
|
9 |
50.29%
|
March 31, 2024 | USD 15.82 | -0.37% |
|
India |
|
10 |
48.75%
|
March 31, 2024 | USD 1.41 | 4.27% |
|
India |
|
11 |
47.90%
|
March 31, 2024 | USD 31.35 | -1.26% |
|
India |
|
12 |
47.39%
|
March 31, 2024 | USD 6.72 | 2.11% |
|
India |
|
13 |
46.75%
|
March 31, 2024 | USD 32.53 | 1.58% |
|
India |
|
14 |
45.85%
|
March 31, 2024 | USD 16.98 | -3.69% |
|
India |
|
15 |
44.96%
|
March 31, 2024 | USD 29.54 | -1.50% |
|
India |
|
16 |
43.83%
|
March 31, 2024 | USD 12.19 | 0.62% |
|
India |
|
17 |
43.83%
|
March 31, 2024 | USD 58.78 | 0.08% |
|
India |
|
18 |
43.79%
|
March 31, 2024 | USD 5.89 | 3.26% |
|
India |
|
19 |
43.09%
|
March 31, 2024 | USD 26.96 | 3.45% |
|
India |
|
20 |
42.77%
|
Dec. 31, 2023 | USD 64.30 | -0.35% |
|
India |
|
21 |
41.36%
|
March 31, 2024 | USD 12.53 | 0.37% |
|
India |
|
22 |
41.01%
|
March 31, 2024 | USD 16.73 | 0.74% |
|
India |
|
23 |
40.20%
|
March 31, 2024 | USD 3.99 | -4.57% |
|
India |
|
24 |
40.20%
|
March 31, 2024 | USD 0.82 | 4.34% |
|
India |
|
25 |
39.54%
|
March 31, 2024 | USD 30.80 | 2.84% |
|
India |
|
26 |
39.38%
|
March 31, 2024 | USD 23.94 | -0.87% |
|
India |
|
27 |
39.38%
|
March 31, 2024 | USD 23.77 | 2.82% |
|
India |
|
28 |
39.33%
|
March 31, 2024 | USD 11.77 | 3.20% |
|
India |
|
29 |
39.16%
|
March 31, 2024 | USD 19.80 | 0.45% |
|
India |
|
30 |
38.87%
|
March 31, 2024 | USD 32.39 | -1.98% |
|
India |
|
31 |
38.83%
|
March 31, 2024 | USD 18.35 | 0.69% |
|
India |
|
32 |
38.58%
|
March 31, 2024 | USD 5.41 | 1.94% |
|
India |
|
33 |
36.82%
|
March 31, 2024 | USD 14.32 | 5.64% |
|
India |
|
34 |
36.17%
|
March 31, 2024 | USD 6.46 | -0.88% |
|
India |
|
35 |
36.03%
|
March 31, 2024 | USD 13.57 | 1.28% |
|
India |
|
36 |
35.87%
|
March 31, 2024 | USD 5.42 | -1.33% |
|
India |
|
37 |
35.78%
|
March 31, 2024 | USD 2.98 | 3.96% |
|
India |
|
38 |
35.75%
|
March 31, 2024 | USD 11.92 | 0.63% |
|
India |
|
39 |
34.53%
|
March 31, 2024 | USD 81.26 | -0.29% |
|
India |
|
40 |
34.45%
|
March 31, 2024 | USD 4.48 | 6.30% |
|
India |
|
41 |
34.13%
|
March 31, 2024 | USD 2.90 | 2.02% |
|
India |
|
42 |
34.12%
|
March 31, 2024 | USD 153.69 | 1.58% |
|
India |
|
43 |
33.78%
|
March 31, 2024 | USD 7.31 | 5.03% |
|
India |
|
44 |
33.61%
|
March 31, 2024 | USD 3.31 | 2.44% |
|
India |
|
45 |
33.58%
|
March 31, 2024 | USD 1.88 | 2.21% |
|
India |
|
46 |
32.84%
|
March 31, 2024 | USD 9.14 | 3.15% |
|
India |
|
47 |
32.62%
|
March 31, 2024 | USD 9.00 | 6.34% |
|
India |
|
48 |
32.14%
|
March 31, 2024 | USD 3.36 | -0.01% |
|
India |
|
49 |
31.09%
|
March 31, 2024 | USD 4.73 | 0.12% |
|
India |
|
50 |
29.88%
|
March 31, 2024 | USD 1.16 | 2.62% |
|
India |
The Pharmaceuticals company in India with the highest Operating Income Margin is Archean Chemical Industries Limited (NSE: ACI.NS) at 85.27%.
The Pharmaceuticals company in India with the lowest Operating Income Margin is Suven Life Sciences Limited (NSE: SUVEN.NS) at -1,048.35%.
The top 10 Pharmaceuticals companies in India by Operating Income Margin are Archean Chemical Industries Limited, Piramal Enterprises Limited, NATCO Pharma Limited, Concord Biotech Limited, Par Drugs and Chemicals Limited, Krishna Institute of Medical Sciences Limited, Cupid Limited, Procter & Gamble Health Limited, Clean Science and Technology Limited and Alembic Limited.
The bottom 10 Pharmaceuticals companies in India by Operating Income Margin are Suven Life Sciences Limited, Sun Pharma Advanced Research Company Limited, Dhani Services Limited, TAKE Solutions Limited, Solara Active Pharma Sciences Limited, Krebs Biochemicals & Industries Limited, Kaya Limited, Astec LifeSciences Limited, Lasa Supergenerics Limited and Zota Health Care Limited.